Several studies have demonstrated that SLC2A1 overexpression is associated with poor clinical outcomes in various types of malignancies [4, 9, 10, 34], but the precise mechanisms by which SLC2A1 could elevate glucose uptake in cancer cells are not fully understood. Here, SLC2A1 is linked to cancer.